Olaparib (AZD2281): Selective PARP-1/2 Inhibitor for BRCA-Deficient Cancer Research

Executive Summary: Olaparib (AZD2281, Ku-0059436) is a potent and selective inhibitor of poly(ADP-ribose) polymerase-1 and -2 (PARP-1/2), with IC50 values of 5 nM and 1 nM, respectively, under in vitro assay conditions (McCrorie et al. 2020). Its action impairs single-strand DNA break repair, preferentially killing BRCA-deficient and homologous recombination-deficient cancer cells (DOI). Olaparib has demonstrated radiosensitizing effects in non-small cell lung carcinoma (NSCLC) and glioblastoma models, enhancing DNA damage and tumor perfusion. The compound is integral for DNA damage response assays and tumor radiosensitization studies, with defined solubility and dosing parameters for preclinical workflows (APExBIO). Sensitivity to olaparib is modulated by ATM kinase activity, with ATM-deficient cells exhibiting increased susceptibility (HMN-214).

Biological Rationale

Poly(ADP-ribose) polymerases (PARP-1/2) play critical roles in the repair of single-strand DNA breaks through the base excision repair (BER) pathway (McCrorie et al. 2020). Inhibition of PARP-1/2 leads to accumulation of DNA lesions, which can convert into double-strand breaks during DNA replication. Cells with deficient homologous recombination repair (HRR), such as those with BRCA1 or BRCA2 mutations, are unable to efficiently repair these breaks, resulting in selective cytotoxicity—a phenomenon termed 'synthetic lethality'. This underpins the rationale for using PARP inhibitors like olaparib in BRCA-associated cancer models and broader studies of homologous recombination deficiency.

Mechanism of Action of Olaparib (AZD2281, Ku-0059436)

Olaparib binds to the catalytic domain of PARP-1 and PARP-2, preventing the transfer of ADP-ribose units to target proteins and thus blocking the recruitment of DNA repair factors (DOI). The resulting impairment of single-strand DNA break repair leads to stalled replication forks and the conversion of unrepaired SSBs to double-strand breaks (DSBs). In HRR-deficient cells, this triggers cell death. Olaparib shows high selectivity: PARP-1 inhibition IC50 = 5 nM, PARP-2 inhibition IC50 = 1 nM, measured at 37°C in cell-free enzymatic assays (APExBIO).

Additional mechanistic insights reveal that olaparib enhances radiosensitivity in tumor models, in part by increasing accumulation of DNA damage and modulating tumor microenvironment perfusion. The sensitivity of cancer cells to olaparib is further influenced by the status of ATM kinase, with ATM-deficient contexts showing heightened susceptibility (HMN-214).

Evidence & Benchmarks

• Olaparib (AZD2281) nanocrystals exhibit high drug loading and in vitro stability, releasing drug over 120 hours under physiological conditions (37°C, pH 7.4) (McCrorie et al. 2020).
• In vivo, olaparib administered intraperitoneally at 50 mg/kg/day for 14 days in mouse models achieves significant tumor cytotoxicity in BRCA-deficient xenografts (DOI).
• Olaparib is effective at 10 μM for 1 hour in standard cell culture DNA damage response assays, with clear induction of γH2AX foci in HRR-deficient cells (ABT-888.com).
• Solubility in DMSO is ≥21.72 mg/mL; olaparib is insoluble in ethanol and water at room temperature (25°C), as per product specification (APExBIO).
• ATM kinase deficiency enhances cellular sensitivity to olaparib-induced DNA damage, as observed in isogenic cancer cell line models (HMN-214).
• Radiosensitization by olaparib has been demonstrated in non-small cell lung carcinoma (NSCLC) xenograft models, resulting in increased tumor perfusion and greater DNA damage post-irradiation (Vitamin D BP).

Applications, Limits & Misconceptions

Applications: Olaparib is widely used in:

• DNA damage response assays to quantify homologous recombination deficiency.
• Targeted therapy research in BRCA1/2-mutant cell and animal models.
• Radiosensitization studies in diverse tumor models, including NSCLC and glioblastoma.
• Assessment of drug resistance mechanisms, such as platinum resistance mediated by Cdc2-like kinase 2 (AZD2281.com).

This article expands on the mechanistic and translational insights from ABT-888.com by providing new benchmarks from polymer-coated nanoparticle delivery models.

Common Pitfalls or Misconceptions

• Ineffective in HRR-proficient cells: Olaparib does not confer significant cytotoxicity in cancer models with intact homologous recombination repair.
• Solubility limitations: The compound is insoluble in ethanol and water, which complicates formulation outside DMSO-based systems.
• Long-term solution instability: Olaparib stock solutions are not recommended for extended storage above -20°C or in solution form.
• Blood-brain barrier (BBB) restriction: Systemic delivery is limited in brain tumor models due to the BBB, motivating localized delivery strategies (DOI).
• ATM and resistance context: Sensitivity is modulated by ATM kinase status; not all DNA repair-deficient tumors are equally susceptible.

Workflow Integration & Parameters

Stock Preparation: Dissolve olaparib at ≥21.72 mg/mL in DMSO. Vortex until fully dissolved at room temperature. Avoid ethanol and water as solvents.

Storage: Store solid powder and stock solutions below -20°C. Avoid repeated freeze-thaw cycles. Prepare working solutions fresh; do not store long-term in solution.

In Vitro Use: Treat cells at 10 μM for 1 hour to induce DNA damage response in HRR-deficient models. Confirm cytotoxicity with γH2AX or caspase activation assays.

In Vivo Use: Intraperitoneal dosing at 50 mg/kg/day for 14 days in mouse xenograft models is standard for efficacy studies (McCrorie et al. 2020).

Radiosensitization: Combine olaparib with irradiation (e.g., 2–6 Gy) in NSCLC or glioblastoma models to assess synergistic effects (Vitamin D BP).

For more detailed workflow parameters and resistance context, see Strategic Advances in BRCA-Deficient Cancer Research, which this article updates with new nanoparticle delivery benchmarks.

Conclusion & Outlook

Olaparib (AZD2281, Ku-0059436) from APExBIO remains a central tool for mechanistic and translational investigation in BRCA-associated and homologous recombination-deficient cancer research. Its selective PARP-1/2 inhibition, robust in vitro and in vivo benchmarks, and compatibility with advanced delivery systems (such as polymer-coated nanoparticles and bioadhesive hydrogels) underscore its utility for next-generation DNA damage response and tumor radiosensitization studies. Future research should prioritize resistance mechanisms and localized delivery strategies, particularly for brain tumor models where systemic delivery is hindered by the blood-brain barrier.